Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa Randomized, Double-blind, and Placebo-controlled Multicenter Split Body Trial of Repeated Doses of ACOU085 for the Prevention of Hearing Loss in Testicular Cancer Patients Receiving Cisplatin

NCT06521190 is registered in ClinicalTrials.gov with Acousia Therapeutics GmbH as lead sponsor.

NCT NCT06521190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06521190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa Randomized, Double-blind, and Placebo-controlled Multicenter Split Body Trial of Repeated Doses of ACOU085 for the Prevention of Hearing Loss in Testicular Cancer Patients Receiving Cisplatin
Lead sponsor
Acousia Therapeutics GmbH
Phase
Phase 2
Overall status
Unknown status
Start date
December 15, 2023
Completion date
September 30, 2025
Enrollment
40 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

cisplatin-induced hearing loss